false
OasisLMS
Catalog
SCCM Resource Library
A Whistle Stop Tour of Drugs!
A Whistle Stop Tour of Drugs!
Back to course
[Please upgrade your browser to play this video content]
Video Transcription
Video Summary
The speaker gives a brief overview of three rare drugs related to diabetes, hemolytic anemia, and myasthenia gravis. The first drug, terdzipetide, is a weekly subcutaneous injection used for type 2 diabetes patients. It works as a double receptor agonist of GLP-1 and GIP, increasing insulin sensitivity and delaying gastric emptying. The second drug, Mitopivate, is an oral tablet for adult patients with pyruvate kinase deficiency and hemolytic anemia. It increases pyruvate kinase activity, ATP levels, and RBC lifespan. The last drug, efgarticamode, is an IV injection for myasthenia gravis patients. It blocks the neonatal FC receptor, reducing harmful acetylcholine receptor antibodies. Monitoring glucose, hemoglobin levels, and immune system function is important while using these medications.
Asset Subtitle
Pharmacology, 2023
Asset Caption
Type: two-hour concurrent | Immunomodulation in Critical Illness: A 2023 Update (SessionID 1161720)
Meta Tag
Content Type
Presentation
Knowledge Area
Pharmacology
Membership Level
Professional
Membership Level
Select
Tag
Pharmacology
Year
2023
Keywords
diabetes
hemolytic anemia
myasthenia gravis
terdzipetide
Mitopivate
×
Please select your language
1
English